**ADULT Medication Monograph**

**CARBOPROST**

This document should be read in conjunction with this DISCLAIMER

⚠️ HIGH RISK
Do not use in women with cardiac or pulmonary disease, hepatic or renal insufficiency, or allergy to prostaglandins. Use with caution in women with asthma

**SAS Category A** (item requires approval by TGA)

| Presentation | Ampoule: 250microg/mL (SAS)  
Also known as 15-methyl prostaglandin F2α |
| Dose | **Primary Postpartum Haemorrhage** (as part of management pathway)  
**IM:**  
250microg.  
If uterus still atonic after 15 minutes repeat dose, and arrange a Cat 1 transfer to theatre. In theatre, doses can be repeated every 15 minutes to a maximum total dose of 2mg (8 ampoules) |
| Administration | IM Injection ONLY |
| Pregnancy |  
1<sup>st</sup> Trimester: Contraindicated  
2<sup>nd</sup> Trimester: Contraindicated  
3<sup>rd</sup> Trimester: Contraindicated |
| Breastfeeding | Commonly used in obstetrics without complications in breastfeeding mothers |
| Monitoring | Do not use in women with cardiac or pulmonary disease, hepatic or renal insufficiency, or allergy to prostaglandins. Use with caution in women with asthma |
| Clinical guidelines and protocols | KEMH Clinical Guideline: O&G: [Primary Postpartum Haemorrhage (Intranet Only)](http://www.medsmilk.com) 
KEMH Clinical Guideline: O&G: [Pharmacological Management of Uterine Tone and Caesarean Birth](http://www.medsmilk.com) |
Keywords: Carboprost, primary postpartum haemorrhage, PPH, dinoprost, prostaglandin F2α, prostaglandin F2-alpha

Publishing: ☑ Intranet ☑ Internet

Document owner: Chief Pharmacist

Author / Reviewer: KEMH Pharmacy Department

Date first issued: June 2015 Version: 3.2

Last reviewed: March 2017, June 2018, March 2020 Next review date: June 2021

Endorsed by: Medicines and Therapeutics Committee Date: Jan 2019

Standards Applicable: NSQHS Standards: 1 Governance, 4 Medication Safety

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2018